Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 2, 2025Journal of Clinical MedicineOpen Access

Update on the Treatment of Non-Small Cell Lung Carcinoma (NSCLC)

View Full Paper
Ask AI
Bookmark
Share

Authors

YKYousif A. Kariri

Discussion

Loading...

Member takes

Overview

This review highlights novel therapies for non-small cell lung carcinoma, demonstrating improved efficacy and safety profiles, suggesting potential for better long-term outcomes.

Key Points

  • The review finds that immune checkpoint medications show improved safety and efficacy in treating non-small cell lung carcinoma.
  • Several therapies including osimertinib and durvalumab are identified as effective in phase IV trials.
  • Analysis focuses on mechanisms of action and adverse effects of treatments such as chemotherapy and immune checkpoint inhibitors.
  • Improving the safety and efficacy of currently available therapies is essential to enhance patient outcomes.

Cite This Study

Yousif A. Kariri (2025) studied this question.

synapsesocial.com/papers/68de5da783cbc991d0a20e2fhttps://doi.org/10.3390/jcm14196960
View Full Paper
Ask AI
Bookmark
Share